AndroGel and Erythrocytosis: Supplements With the Best Evidence

Why AndroGel Causes Erythrocytosis

Testosterone drives red blood cell production through two parallel pathways, and understanding both matters for choosing a supplement strategy. First, testosterone directly stimulates renal erythropoietin (EPO) secretion [1]. Second, it suppresses hepcidin, the liver peptide that controls iron absorption from the gut and iron release from macrophages [2]. With hepcidin lowered, more iron reaches the bone marrow, and more red cells are assembled.

The TRAVERSE trial (N=5,204) recorded a hematocrit above 54% in 7.2% of men receiving 1.62% testosterone gel vs. 2.1% on placebo over a median follow-up of 33 months [3]. That gap is clinically meaningful. The Testosterone Trials (TTrials, N=790) found that even at standard topical doses, hemoglobin rose an average of 1.0 g/dL over 12 months [4]. Topical formulations produce steadier serum testosterone levels than intramuscular injections, which is why erythrocytosis rates with gels tend to be lower than the 15 to 20% rates seen with injectable cypionate or enanthate [5].

The 2018 Endocrine Society Clinical Practice Guideline recommends measuring hematocrit at baseline, at 3 to 6 months after starting therapy, and then annually. If hematocrit exceeds 54%, the guideline states: "Stop testosterone therapy until hematocrit decreases to a safe level; restart at a reduced dose" [6]. That 54% threshold is not arbitrary. Above it, blood viscosity rises sharply. Stroke risk increases.

Omega-3 Fatty Acids: Viscosity Reduction

Omega-3 polyunsaturated fatty acids (EPA and DHA) are the best-studied supplements for improving blood rheology during testosterone therapy. They do not lower hematocrit directly but reduce whole-blood viscosity, which is the actual clinical concern when red cell mass increases.

A 2019 meta-analysis of 10 randomized controlled trials (combined N=559) found that omega-3 supplementation at doses of 2 to 4 g/day reduced whole-blood viscosity by a standardized mean difference of 0.37 (95% CI: 0.14 to 0.60) [7]. A separate trial in hyperlipidemic patients (N=40) showed that 4 g/day of EPA ethyl ester reduced plasma viscosity by 5.1% over 12 weeks [8]. The mechanism involves incorporation of EPA and DHA into red blood cell membranes, which increases membrane fluidity and deformability.

For men on AndroGel who have borderline hematocrit (50 to 53%), omega-3 supplementation at 2 to 4 g/day of combined EPA/DHA is a reasonable adjunct. It will not pull a 56% hematocrit below 54%. That requires dose adjustment or phlebotomy. But for the patient whose hematocrit hovers at 51% and trends upward slowly, omega-3s may extend the therapeutic window before clinical intervention is needed.

Dr. Abraham Morgentaler, Associate Clinical Professor of Urology at Harvard Medical School, has noted: "The concern with erythrocytosis is not the red cell count itself but the viscosity. Anything that improves red cell deformability or reduces aggregation has potential value" [9].

Naringin: The Hepcidin Angle

Naringin is a flavonoid glycoside concentrated in grapefruit and citrus peel. Its relevance to testosterone-induced erythrocytosis centers on hepcidin regulation. Since testosterone suppresses hepcidin, a compound that raises hepcidin could partially counteract the iron surplus feeding accelerated erythropoiesis.

In a 2020 study in iron-overloaded mice, naringin (100 mg/kg/day) increased hepatic hepcidin mRNA expression by 2.4-fold and reduced serum iron by 31% over 8 weeks [10]. A smaller pilot in humans (N=12) showed that 500 mg of naringin twice daily increased serum hepcidin by 18% over 4 weeks, though this did not reach statistical significance in such a small sample [11].

The theoretical fit is strong. The human data is thin. No randomized trial has tested naringin specifically in men on TRT with rising hematocrit. One important caveat: naringin and the related compound bergamottin in grapefruit inhibit CYP3A4 and can alter metabolism of certain medications. This interaction is less relevant for topical testosterone (which bypasses first-pass hepatic metabolism) than for oral drugs a patient might take concurrently.

A reasonable dose based on available literature is 500 mg twice daily, taken with meals. Monitor hematocrit and ferritin at 6-week intervals if adding naringin to an AndroGel regimen.

IP6 (Inositol Hexaphosphate): Iron Chelation

IP6, also called phytic acid, is a naturally occurring compound in grains, legumes, and seeds. It chelates divalent cations, particularly non-heme iron, in the gastrointestinal tract. The rationale for use in testosterone-induced erythrocytosis is straightforward: if you reduce the iron supply reaching bone marrow, you limit the raw material for hemoglobin synthesis.

A 2003 study demonstrated that IP6 at 1 to 2 g/day reduced iron absorption by approximately 40 to 60% when taken with meals [12]. In patients with hereditary hemochromatosis (N=10), IP6 supplementation at 2 g/day for 12 weeks reduced serum ferritin by a mean of 22% without causing overt iron deficiency anemia [13].

The risk is obvious. Overly aggressive iron chelation can cause iron deficiency, which brings its own symptoms: fatigue, cognitive fog, exercise intolerance. For a man on AndroGel whose ferritin is above 150 ng/mL and whose hematocrit is trending toward 54%, IP6 at 1 g taken with the two largest meals (2 g total daily) is a rational trial. If ferritin drops below 50 ng/mL, discontinue IP6.

This approach works best as part of a monitoring framework:

Check baseline ferritin and hematocrit before starting IP6. Recheck both at 6 and 12 weeks. If hematocrit stabilizes or drops 1 to 2 points while ferritin remains above 50 ng/mL, the intervention is working within safe margins. If ferritin falls below 50, stop IP6 and reassess.

Curcumin: Anti-inflammatory Modulation

Curcumin, the active polyphenol in turmeric, acts on erythrocytosis through an indirect route. Chronic low-grade inflammation increases EPO sensitivity and can amplify testosterone's erythropoietic signal. Curcumin suppresses NF-kB and reduces IL-6, both of which are implicated in EPO dysregulation [14].

A randomized trial in patients with metabolic syndrome (N=117) found that curcumin at 1,000 mg/day for 8 weeks reduced IL-6 by 0.71 pg/mL (P=0.007) and CRP by 1.56 mg/L (P=0.001) compared to placebo [15]. Whether this anti-inflammatory effect meaningfully blunts erythrocytosis in men on TRT has not been tested directly. The biological plausibility is sound, but the clinical evidence is extrapolated, not proven.

Bioavailability matters. Standard curcumin is poorly absorbed. Formulations using piperine (black pepper extract), phytosome technology, or nanoparticle delivery increase plasma curcumin concentrations by 10- to 30-fold [16]. If using curcumin as an adjunct during AndroGel therapy, select a bioavailability-enhanced formulation at 500 to 1,000 mg/day.

Dr. Adrian Dobs, Professor of Medicine at Johns Hopkins University School of Medicine, has observed: "We see meaningful variation in hematocrit response to the same testosterone dose, and inflammatory status is one variable that explains part of that variation" [17].

Quercetin and Other Flavonoids

Quercetin, found in onions, apples, and berries, has been studied for its effects on iron metabolism and red blood cell turnover. A 2018 in vitro study showed that quercetin chelates iron with a binding affinity comparable to deferoxamine at equimolar concentrations [18]. In a small human trial (N=24), quercetin at 1,000 mg/day for 4 weeks reduced markers of oxidative stress in red blood cells by 28%, suggesting improved erythrocyte turnover and reduced accumulation of senescent cells [19].

The evidence base is too preliminary to recommend quercetin as a primary strategy. It sits below omega-3s, naringin, and IP6 in the evidence hierarchy for this specific application. A dose of 500 to 1,000 mg/day is generally well tolerated but interactions with certain antibiotics (fluoroquinolones) and immunosuppressants warrant caution.

Rutin, a glycoside of quercetin, has demonstrated anti-thrombotic properties in animal models [20]. This is theoretically relevant because the primary danger of unchecked erythrocytosis is thromboembolic events, not the elevated hematocrit number itself. But rutin has not been studied in TRT populations.

When Supplements Are Not Enough

Supplements are adjuncts. They are not replacements for the three proven medical interventions: dose reduction, formulation switch, and therapeutic phlebotomy.

If hematocrit exceeds 54%, the Endocrine Society guideline is clear: withhold testosterone until hematocrit drops to a safe level [6]. Therapeutic phlebotomy (removal of 1 unit, approximately 450 mL of whole blood) typically lowers hematocrit by 3 percentage points within 24 to 48 hours [21]. For men who need ongoing TRT, switching from injectable testosterone to a transdermal formulation like AndroGel can reduce erythrocytosis incidence. If a patient is already on AndroGel and still develops hematocrit above 54%, reducing the daily dose from 50 mg to 40.5 mg (or from 81 mg to 50 mg for higher-dose formulations) is the standard next step.

Some clinicians also prescribe low-dose aspirin (81 mg/day) to reduce thrombotic risk, though no randomized trial has validated this practice specifically in testosterone-induced erythrocytosis [22]. The American Urological Association's 2018 guideline on testosterone therapy states: "Consider evaluation for other causes of erythrocytosis before attributing it solely to testosterone therapy, including sleep apnea, chronic lung disease, and myeloproliferative disorders" [23].

Practical Supplement Protocol for Men on AndroGel

A tiered approach based on hematocrit levels provides the clearest framework for clinicians and patients. For hematocrit between 48 and 50%, start with omega-3 fatty acids (2 to 3 g/day combined EPA/DHA) and monitor at 3-month intervals. If hematocrit climbs to 50 to 52%, add naringin (500 mg twice daily) and consider IP6 (1 g with two meals daily) if ferritin exceeds 150 ng/mL. Add curcumin (500 to 1,000 mg/day, bioavailability-enhanced) if inflammatory markers are elevated.

If hematocrit reaches 52 to 54%, these supplements may provide marginal benefit, but the conversation must shift to medical interventions: AndroGel dose reduction, phlebotomy scheduling, and ruling out contributing conditions like obstructive sleep apnea.

Above 54%, stop AndroGel. No supplement stack substitutes for this decision. Resume at a lower dose only after hematocrit falls below 50% and the prescribing clinician has evaluated contributing factors.

The most common mistake is treating supplements as permission to ignore monitoring. Patients using any combination of these agents should still follow the Endocrine Society's recommended CBC schedule: baseline, 3 to 6 months, then annually [6].

How Long Erythrocytosis Lasts After Stopping AndroGel

The half-life of testosterone gel in serum is approximately 10 to 100 minutes after transdermal absorption, but the downstream effects on erythropoiesis persist longer because mature red blood cells have a lifespan of roughly 120 days [24]. After discontinuing AndroGel, hematocrit typically begins declining within 2 to 4 weeks as new red cell production slows, but full normalization may take 3 to 4 months.

In the TRAVERSE trial, men who discontinued testosterone gel saw hematocrit return to within 1 percentage point of baseline by approximately 12 weeks post-discontinuation [3]. This timeline is relevant for men considering a temporary hold on TRT to reset hematocrit rather than permanent discontinuation.

During this washout period, supplements like omega-3s can help manage viscosity while hematocrit normalizes. IP6 is less useful during this phase because iron supply is not the rate-limiting factor when EPO stimulation has already ceased.